| Item type |
文献 / Documents(1) |
| 公開日 |
2021-06-14 |
| アクセス権 |
|
|
アクセス権 |
open access |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| 出版社版DOI |
|
|
|
関連識別子 |
https://doi.org/10.1111/cas.14329 |
|
|
関連名称 |
10.1111/cas.14329 |
| 出版タイプ |
|
|
出版タイプ |
VoR |
|
出版タイプResource |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| タイトル |
|
|
タイトル |
Theracurmin inhibits intestinal polyp development in Apc‐mutant mice by inhibiting inflammation‐related factors |
| 著者 |
アダチ, サエコ
ハモヤ, タカヒロ
フジイ, ゲン
ナリタ, タクミ
コミヤ, マサミ
ミヤモト, シンゴ
クロカワ, ユリエ
タカハシ, マイコ
高山, 哲治
イシカワ, ヒデキ
タシロ, コウスケ
ムトウ, ミチヒロ
|
| 抄録 |
|
|
内容記述 |
Colorectal cancer (CRC) is the second leading cause of cancer death worldwide. Therefore, it is important to establish useful methods for preventing CRC. One prevention strategy involves the use of cancer chemopreventive agents, including functional foods. We focused on the well‐known cancer chemopreventive agent curcumin, which is derived from turmeric. However, curcumin has the disadvantage of being poorly soluble in water due to its high hydrophobicity. To overcome this problem, the formation of submicron particles with surface controlled technology has been applied to curcumin to give it remarkably improved water solubility, and this derived compound is named Theracurmin. To date, the preventive effects of Theracurmin on hereditary intestinal carcinogenesis have not been elucidated. Thus, we used Apc‐mutant mice, a model of familial adenomatous polyposis, to evaluate the effects of Theracurmin. First, we showed that treatment with 10‐20 µM Theracurmin for 24 hours reduced nuclear factor‐κB (NF‐κB) transcriptional activity in human colon cancer DLD‐1 and HCT116 cells. However, treatment with curcumin mixed in water did not change the NF‐κB promoter transcriptional activity. As NF‐κB is a regulator of inflammation‐related factors, we next investigated the downstream targets of NF‐κB: monocyte chemoattractant protein‐1 (MCP‐1) and interleukin (IL)‐6. We found that treatment with 500 ppm Theracurmin for 8 weeks inhibited intestinal polyp development and suppressed MCP‐1 and IL‐6 mRNA expression levels in the parts of the intestine with polyps. This report provides a proof of concept for the ongoing Theracurmin human trial (J‐CAP‐C study). |
| キーワード |
|
|
主題 |
colorectal cancer chemoprevention |
| キーワード |
|
|
主題 |
curcumin |
| キーワード |
|
|
主題 |
min mice |
| キーワード |
|
|
主題 |
nuclear factor-κB |
| キーワード |
|
|
主題 |
Theracurmin |
| 書誌情報 |
en : Cancer Science
巻 111,
号 4,
p. 1367-1374,
発行日 2020-01-28
|
| 収録物ID |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
13497006 |
| 出版者 |
|
|
出版者 |
Japanese Cancer Association |
| 出版者 |
|
|
出版者 |
John Wiley & Sons |
| 権利情報 |
|
|
権利情報 |
This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial License(https://creativecommons.org/licenses/by-nc/4.0/), which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
| EID |
|
|
識別子 |
368479 |
| 言語 |
|
|
言語 |
eng |
cas_111_4_1367.pdf (623 KB)
.png)
